Research
Original data & PubMed-cited science on GLP-1 weight loss.
We track every major GLP-1 telehealth provider in the United States and publish two kinds of long-form pieces: data investigations using our live dataset, and PubMed-cited scientific deep-dives on the studies that actually matter. Both update as the underlying data changes.
Research formats
Related tools
- Scientific deep-dive5 min · 3 sources
What Is Petrelintide? Zealand's Long-Acting Amylin Analog
Petrelintide is an investigational long-acting human amylin analog from Zealand Pharma. Like cagrilintide it works on the amylin system rather than GLP-1 — a genuinely different mechanism, not a stronger version of what is already on the market. The interest in the class is partly added weight loss and substantially tolerability. The published clinical evidence is two randomized, controlled phase 1 trials reporting safety, tolerability and pharmacokinetics, which is far earlier than most compounds people research, and early-phase estimates move as trials get larger.
Read the analysis→ - Scientific deep-dive5 min · 3 sources
What Is Survodutide? The Glucagon/GLP-1 Dual Agonist in Phase 3
Survodutide is an investigational once-weekly glucagon/GLP-1 receptor dual agonist from Boehringer Ingelheim and Zealand Pharma, with a phase 3 obesity trial published in NEJM in 2026 on top of phase 2 dose-finding work and a separate phase 2 trial in MASH with fibrosis. It targets the same receptor pair as mazdutide, so the difference between them is regulatory rather than mechanistic. Against tirzepatide the difference is real — glucagon rather than GIP as the second receptor — but no randomized trial has compared them, so any percentage-versus-percentage claim is cross-trial guesswork.
Read the analysis→ - Scientific deep-dive6 min · 3 sources
What Is Mazdutide? The Obesity Drug Approved in China, Not the US
Mazdutide is unusual: not a pipeline compound, not a gray-market peptide, but an approved medicine — approved by China's NMPA for chronic weight management, and reported in the literature as a first approval for its class. It has no US approval, which is the whole reason it confuses people. It pairs glucagon with GLP-1, the same two receptors as survodutide, where tirzepatide pairs GIP with GLP-1. The pivotal trials were run in Chinese adults and published in NEJM and Nature. An approval in one country is not an approval in yours.
Read the analysis→ - Scientific deep-dive6 min · 4 sources
What Is Cagrilintide? The Amylin Analog Behind CagriSema
Cagrilintide is an amylin analog — a different hormone system from GLP-1, which is why researchers describe amylin analogs as the next major class rather than the next GLP-1. It is best known as the other half of CagriSema, the fixed-dose combination with semaglutide. Neither has a US label: DailyMed returned zero results for both names on 19 August 2026. A 2026 meta-analysis pooling 4 RCTs and 5,425 participants found 6.08% body-weight reduction for cagrilintide monotherapy, with no meaningful HbA1c change and substantial heterogeneity. Here is what the evidence shows, and why the dosage chart people search for does not exist.
Read the analysis→ - Scientific deep-dive6 min · 3 sources
What Is GLP-3? There Is No Such Hormone — Here's What People Mean
There is no such thing as GLP-3 — no hormone, no receptor, no approved drug, and no FDA label containing the term. What people mean is retatrutide, Eli Lilly's investigational molecule that hits three receptors at once: GLP-1, GIP, and glucagon. The 3 counts receptors, not generations. GLP-2 is real but treats short bowel syndrome, not obesity, so the GLP-1 → GLP-2 → GLP-3 progression people describe does not exist. Because retatrutide is still in phase 3 and has no approved product, the nickname has become the label under which unapproved material is sold as “GLP-3 peptide,” “GLP-3 R,” and “GLP-3 RT.”
Read the analysis→ - Scientific deep-dive6 min · 4 sources
Syringe Dead Space and GLP-1 Dosing: The Small Error That Scales
Why a more concentrated vial makes every fixed measuring error larger, and what actually reduces it.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
“Same Molecule” Is Not the Same Product: Compounded GLP-1 Impurities
What has actually been measured about compounded GLP-1 purity, and the questions worth asking your pharmacy.
Read the analysis→ - Scientific deep-dive6 min · 4 sources
Beyond-Use Dates on Compounded GLP-1s: Not an Expiration Date
What a beyond-use date actually certifies, and the in-use period most labels never mention.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
How Long Can a Compounded GLP-1 Be Out of the Fridge?
Why the brand pen's room-temperature figure does not apply to your compounded vial.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
Why GLP-1 Doses Are Titrated: The Reasoning Behind the Ladder
Why the ladder exists, why the steps are four weeks apart, and when holding a dose is the right call.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
What Is the Starting Dose of Compounded Semaglutide?
The 0.25 mg start, why the steps are four weeks apart, and what compounding changes.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
What Is the Starting Dose of Compounded Tirzepatide?
What the trials actually did at initiation, and what changes when the product is compounded.
Read the analysis→ - Scientific deep-dive8 min · 5 sources
Oral Tirzepatide: Does a Pill Version Exist, and Does It Work?
Why tirzepatide has no pill form, and what oral semaglutide and orforglipron actually did differently.
Read the analysis→ - Scientific deep-dive6 min · 4 sources
Thigh, Abdomen or Arm: Does GLP-1 Injection Site Change Absorption?
What the trial evidence says about injecting a GLP-1 in the thigh versus the stomach — and what rotation is actually for.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
Compounded Semaglutide Dosage in Units: The Conversion, and Why It Goes Wrong
Why “how many mg is 50 units of semaglutide” depends entirely on your vial, and the formula that answers it.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
Compounded Tirzepatide Dosage in Units: Why There Is No Single Answer
Why “how many units is 2.5 mg of tirzepatide” has no fixed answer, and the one formula that does.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
Can Fiber Boost Your Own GLP-1? Propionate and the SCFA Evidence
The science behind 'boost your natural GLP-1' claims — what colon-targeted propionate actually did in randomized human trials.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
Akkermansia muciniphila for Weight Loss: What the Evidence Says
Does the gut bacterium behind 'GLP-1 support' probiotics actually work? Three randomized trials, including one that failed its primary endpoint.
Read the analysis→ - Scientific deep-dive9 min · 9 sources
Does Blurred Vision From Ozempic Go Away? The Refractive-Shift Evidence
Blurry vision early on a GLP-1 is usually your glasses prescription moving, not your eyes being damaged. Here is why it happens, whether it resolves, and how to tell it from the serious cause.
Read the analysis→ - Scientific deep-dive7 min · 1 sources
Zepbound KwikPen vs Single-Dose Pen and Vial: What the Label Requires
The KwikPen is single-patient-use, not single-dose — and the label requires fresh training whenever your presentation changes, which pharmacy switches make easy to miss.
Read the analysis→ - Scientific deep-dive9 min · 4 sources
What Dose of Zepbound Is Most Effective? The SURMOUNT-1 Evidence
15 mg produced the biggest average result in the pivotal trial — but the label treats 5, 10 and 15 mg as equally valid maintenance doses, chosen on response and tolerability.
Read the analysis→ - Scientific deep-dive9 min · 5 sources
How to Reconstitute Tirzepatide: The Concentration Math That Causes Overdoses
Units on a syringe measure volume, not drug. The same vial gives 0.1 mg or 0.025 mg per unit depending on dilution — which is why borrowed unit counts cause overdoses.
Read the analysis→ - Scientific deep-dive8 min · 3 sources
Can You Stay on a Low Dose of Wegovy? What the FDA Label Allows
You may not have to reach 2.4 mg. The FDA label names 1.7 mg as a maintenance option for weight reduction and tells prescribers to choose on response and tolerability.
Read the analysis→ - Scientific deep-dive10 min · 5 sources
Wegovy and Alcohol: Can You Drink on Semaglutide? Interactions & Risks
The FDA Wegovy label has no formal alcohol contraindication — but there are several real interactions: additive GI effects, a hypoglycemia picture that genuinely differs from Ozempic's diabetic population, shared pancreatitis risk, and the weight-loss tradeoff. Here's what each one means, and the growing GLP-1-and-alcohol-cravings research signal.
Read the analysis→
How we work
Every data point in our investigations is verified directly against provider websites, and the dataset updates continuously. Every scientific deep-dive cites primary literature from PubMed, the FDA, or peer-reviewed clinical trials — never blog summaries or marketing pages. Articles are reviewed and revised whenever the underlying evidence base changes.
We do not sell or recommend specific medical treatments — talk to a licensed clinician before starting any medication. Read our full methodology →